Interleukin-7 receptor α mutational activation can initiate precursor B-cell acute lymphoblastic leukemia

Author:

Almeida Afonso R. M.,Neto João L.ORCID,Cachucho Ana,Euzébio Mayara,Meng Xiangyu,Kim RathanaORCID,Fernandes Marta B.ORCID,Raposo Beatriz,Oliveira Mariana L.,Ribeiro Daniel,Fragoso RitaORCID,Zenatti Priscila P.,Soares Tiago,de Matos Mafalda R.,Corrêa Juliana RonchiORCID,Duque MafaldaORCID,Roberts Kathryn G.ORCID,Gu Zhaohui,Qu Chunxu,Pereira Clara,Pyne SusanORCID,Pyne Nigel J.,Barreto Vasco M.,Bernard-Pierrot IsabelleORCID,Clappier Emannuelle,Mullighan Charles G.ORCID,Grosso Ana R.ORCID,Yunes J. AndrésORCID,Barata João T.ORCID

Abstract

AbstractInterleukin-7 receptor α (encoded by IL7R) is essential for lymphoid development. Whether acute lymphoblastic leukemia (ALL)-related IL7R gain-of-function mutations can trigger leukemogenesis remains unclear. Here, we demonstrate that lymphoid-restricted mutant IL7R, expressed at physiological levels in conditional knock-in mice, establishes a pre-leukemic stage in which B-cell precursors display self-renewal ability, initiating leukemia resembling PAX5 P80R or Ph-like human B-ALL. Full transformation associates with transcriptional upregulation of oncogenes such as Myc or Bcl2, downregulation of tumor suppressors such as Ikzf1 or Arid2, and major IL-7R signaling upregulation (involving JAK/STAT5 and PI3K/mTOR), required for leukemia cell viability. Accordingly, maximal signaling drives full penetrance and early leukemia onset in homozygous IL7R mutant animals. Notably, we identify 2 transcriptional subgroups in mouse and human Ph-like ALL, and show that dactolisib and sphingosine-kinase inhibitors are potential treatment avenues for IL-7R-related cases. Our model, a resource to explore the pathophysiology and therapeutic vulnerabilities of B-ALL, demonstrates that IL7R can initiate this malignancy.

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3